Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system

• 主要な著者: Psota M (著者), Psenkova MB (著者), Racekova N (著者), Ramirez de Arellano A (著者), Vandebrouck T (著者), Hunt B (著者)
• フォーマット: 図書
• 出版事項: Dove Medical Press, 2017-12-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Marek Psota,1 Maria Bucek Psenkova,1 Natalia Racekova,2 Antonio Ramirez de Arellano,3 Tom Vandebrouck,4 Barnaby Hunt5 1Pharm-In, Ltd., 2Novo Nordisk Ltd., Bratislava, Slovakia; 3Novo Nordisk Ltd., Madrid, Spain; 4Novo Nordisk nv, Brussels, Belgium; 5Ossian Health Economics and Communications, Basel,...